FBL22_Fbxl22 Inhibitors
FBL22_Fbxl22 inhibitors represent a class of compounds designed to specifically target and impede the activity of the FBL22_Fbxl22 protein, a member of the F-box protein family. FBL22_Fbxl22 plays a crucial role in the ubiquitin-proteasome pathway, which is responsible for the selective degradation of proteins within the cell. These inhibitors function by binding to the FBL22_Fbxl22, thereby obstructing its interaction with the E3 ubiquitin ligase complex, an interaction that is essential for the tagging of substrate proteins with ubiquitin. By preventing this tagging process, FBL22_Fbxl22 inhibitors effectively halt the subsequent proteasomal degradation of these substrates, leading to an accumulation of the said proteins within the cell. The accumulation often results in a regulatory impact on various cellular processes, such as cell cycle progression, signal transduction, and gene expression, as these processes are often tightly controlled by the timely degradation of key regulatory proteins.
The specificity of FBL22_Fbxl22 inhibitors is paramount to their function as it ensures minimal off-target effects, which is a common challenge in the development of inhibitors that target ubiquitin-mediated proteolysis. The inhibitors are characterized by their ability to engage with the FBL22_Fbxl22 protein at its substrate-binding site or at allosteric sites that induce conformational changes, rendering the protein inactive. This specificity is achieved through the meticulous design of the inhibitors, often leveraging structural data on FBL22_Fbxl22 to identify potential binding pockets that are unique to this protein. By doing so, the inhibitors can provide a targeted approach to disrupting the protein-protein interactions that FBL22_Fbxl22 mediates, further elucidating the role of these interactions in the regulation of protein turnover. The action of these inhibitors underscores the intricate balance within cellular systems, where the disruption of a single protein's function can cascade into broader cellular effects, highlighting the interconnected nature of proteostasis networks.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that binds to the tyrosine kinase domain of EGFR, preventing its activation. As FBL22_Fbxl22 is involved in the ubiquitination and subsequent degradation of proteins in the EGFR signaling pathway, inhibition of EGFR by Gefitinib could reduce the turnover of these proteins, indirectly decreasing the functional activity of FBL22_Fbxl22. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the phosphorylation and activation of PI3K-dependent signaling pathways. FBL22_Fbxl22, which is implicated in the ubiquitin-proteasome system, might be involved in the degradation of key signaling proteins downstream of PI3K. Inhibition of PI3K by LY294002 could therefore reduce the substrate availability for FBL22_Fbxl22-mediated ubiquitination. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTOR signaling pathway, which is crucial for cell growth and proliferation. Since FBL22_Fbxl22 could be implicated in the degradation of proteins regulated by mTOR, the inhibition of mTOR by Rapamycin might indirectly diminish the activity of FBL22_Fbxl22 by stabilizing its substrates. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Given that FBL22_Fbxl22 is part of the ubiquitin-proteasome system, the inhibition of the proteasome by Bortezomib would lead to an accumulation of FBL22_Fbxl22's substrates, potentially reducing the need for its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a reversible proteasome inhibitor, which, like Bortezomib, leads to the accumulation of ubiquitinated proteins. This accumulation could suppress the functional activity of FBL22_Fbxl22 by decreasing the ubiquitination turnover rate. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-β type I receptor ALK5, which modulates the SMAD signaling pathway. If FBL22_Fbxl22 targets proteins in the TGF-β pathway for degradation, inhibition of this pathway by SB431542 could lead to reduced activity of FBL22_Fbxl22. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that interferes with the MAPK/ERK pathway. Since FBL22_Fbxl22 could be involved in targeting proteins in this pathway for ubiquitination, inhibition of the pathway by Trametinib would likely decrease the functional activity of FBL22_Fbxl22 by reducing substrate availability. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $260.00 $1029.00 | ||
Omipalisib is a dual PI3K/mTOR inhibitor, which would not only reduce the PI3K pathway activity but also decrease mTOR signaling. The dual inhibition might have a compounded effect on reducing the substrate proteins for FBL22_Fbxl22-mediated ubiquitination. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an mTOR kinase inhibitor that would suppress mTORC1 and mTORC2 signaling. This comprehensive mTOR inhibition could indirectly affect the functionality of FBL22_Fbxl22 by stabilizing proteins that are normally targeted for degradation by the ubiquitin-proteasome pathway. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 is a PI3K inhibitor that could decrease the activation of downstream AKT signaling, a pathway that may intersect with the functional role of FBL22_Fbxl22. The reduced signaling could lead to decreased substrate availability | ||||||